Abraham GM, et al. – This study focuses on the treatment of chronic hepatitis C disease. Findings reveal that most of the direct–acting antiviral agents (DAAs) for chronic hepatitis C infection had a high barrier to resistance and are extremely well–tolerated by patients. DAAs, in addition, demonstrate 90% or higher efficacy rates.

• The treatment paradigm for chronic hepatitis C infection has dramatically changed with the advent of the direct–acting antiviral agents (DAAs), especially the duration, tolerability and response to therapy.
• The DAAs are classified in to several classes and are variously indicated in the treatment of one or more genotypes of infection.
• All these agents are orally administered, and they, in majority, are eliminated renally (with exceptions), and don’t require adjustment in mild to moderate renal insufficiency.